Samsung Pharm
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, enzyme, mixed vitamin… Read more
Samsung Pharm (001360) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.013x
Based on the latest financial reports, Samsung Pharm (001360) has a cash flow conversion efficiency ratio of -0.013x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.29 Billion) by net assets (₩180.09 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Samsung Pharm - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Samsung Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Samsung Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Samsung Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nicolas Correa SA
MC:NEA
|
0.080x |
|
Compagnie du Cambodge
PA:CBDG
|
0.004x |
|
Identiv Inc
NASDAQ:INVE
|
-0.020x |
|
Bamboo Capital JSC
VN:BCG
|
0.044x |
|
Dry Cell and Storage Battery JSC
VN:PAC
|
N/A |
|
Komelon Corporation
KQ:049430
|
0.017x |
|
Formosa Pharmaceuticals, Inc.
TW:6838
|
-0.018x |
|
Bharat Rasayan Limited
NSE:BHARATRAS
|
0.000x |
Annual Cash Flow Conversion Efficiency for Samsung Pharm (2012–2024)
The table below shows the annual cash flow conversion efficiency of Samsung Pharm from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩105.86 Billion | ₩-17.30 Billion | -0.163x | +54.17% |
| 2023-12-31 | ₩77.58 Billion | ₩-27.66 Billion | -0.356x | -1810.44% |
| 2022-12-31 | ₩102.59 Billion | ₩-1.91 Billion | -0.019x | +66.85% |
| 2021-12-31 | ₩127.27 Billion | ₩-7.16 Billion | -0.056x | -168.73% |
| 2020-12-31 | ₩121.92 Billion | ₩-2.55 Billion | -0.021x | -22.88% |
| 2019-12-31 | ₩142.83 Billion | ₩-2.43 Billion | -0.017x | +65.59% |
| 2018-12-31 | ₩131.66 Billion | ₩-6.52 Billion | -0.050x | -190.23% |
| 2017-12-31 | ₩93.87 Billion | ₩5.15 Billion | 0.055x | +145.48% |
| 2016-12-31 | ₩82.38 Billion | ₩-9.94 Billion | -0.121x | -32.70% |
| 2015-12-31 | ₩46.24 Billion | ₩-4.20 Billion | -0.091x | +84.40% |
| 2014-12-31 | ₩23.29 Billion | ₩-13.58 Billion | -0.583x | -81.92% |
| 2012-12-31 | ₩34.71 Billion | ₩-11.13 Billion | -0.321x | -- |